The addition of spartalizumab to dabrafenib and trametinib demonstrated a long-term survival benefit in patients with BRAF V600–mutant metastatic melanoma, according to the final overall survival analysis from the phase III COMBI-I trial published in the Journal of Clinical Oncology. 

For more than a decade, geriatric oncology has evolved from a niche discipline into an evidence-based component of high-quality cancer care. Landmark randomized trials, including the Geriatric Assessment for Patients 70 Years and Older Starting Cancer Treatment (GAP70+) trial,¹ the Geriatric Assessment-Driven Intervention (GAIN) trial,² the Integrated Geriatric Assessment and Treatment Effectiveness (INTEGERATE) study,³ and the Geriatric Intervention in Frail Older Patients With Cancer Receiving Chemotherapy (GERICO) trial,⁴ have consistently demonstrated that geriatric assessment–guided interventions can reduce treatment toxicity, improve communication and patient-centered care, and support treatment decision-making for older adults with cancer.

First-line treatment with the antibody-drug conjugate sacituzumab govitecan-hziy plus pembrolizumab led to a longer progression-free survival after next line of treatment—ie, progression-free survival–2 (PFS2)—than chemotherapy plus pembrolizumab in patients with previously untreated, PD-L1–positive advanced triple-negative breast cancer, according to an exploratory post hoc analysis of the phase III ASCENT-04/KEYNOTE-D19 trial¹ presented at the 2026 ASCO Annual Meeting by Kevin Kalinsky, MD, MS, FASCO, Professor and Director in the Division of Medical Oncology and Co-Director of the Glenn Family Breast Center at Winship Cancer Institute of Emory University School of Medicine, Atlanta.